InvestorsHub Logo
Followers 826
Posts 119431
Boards Moderated 16
Alias Born 09/05/2002

Re: None

Tuesday, 08/11/2020 11:16:33 AM

Tuesday, August 11, 2020 11:16:33 AM

Post# of 1162
Opdivo/chemo shows statsig OS/PFS benefit vs chemo alone in first-line gastric and esophageal cancer in phase-3 CHECKMATE-649 study:

https://www.businesswire.com/news/home/20200811005245/en

The PFS and OS benefits were seen in the entire patient pool, irrespective of PD-L1 expression.

CHECKMATE-649 has a third arm testing Opdivo + Yervoy (without chemo), but the data from this arm are not yet mature.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News